FDA approves Alembic’s Paroxetine ER tablets
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Ultra-high purity surfactant for biologics and parenteral drug formulations
Relonchem receives marketing authorization for Moxonidine tablets
Prolia is a prescription medicine used to treat osteoporosis in women
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Subscribe To Our Newsletter & Stay Updated